Lu Dai
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
Also affiliated: Changchun University of Science and Technology (2025–2026); Liaoning University (2022–2024); Huaqiao University (2023); The Graduate Center, CUNY (2015); Beijing Institute of Technology (2023–2025); Roche (United States) (2021); Union Hospital (2014); Zhejiang Sci-Tech University (2022); The University of Texas MD Anderson Cancer Center (1993–1999); Zhejiang Normal University (2026); University of Kentucky (2014–2018); East China University of Science and Technology (2025); Medical University of South Carolina (2009–2011); Sun Yat-sen University (2024); China Three Gorges University (2024); Hangzhou Normal University (2017); Hohai University (2016); National University of Defense Technology (2000); Nanyang Technological University (2009–2024); Yangtze University (2023–2025); Guizhou University (2023); University of Bremen (2012); Jilin University (2014–2025); Chinese Academy of Sciences (2025); Peking University (2009–2024); Heidelberg University (2010–2013); Fondazione Bruno Kessler (2012); Fudan University (2010); Kessler Foundation (2012); San Diego State University (1997–1998); Wenzhou Medical University (2023–2024); Cystic Fibrosis Foundation (2010); China Tobacco (2023); Analytical Services (2020–2021); University Hospital Heidelberg (2010); Southern University of Science and Technology (2024–2025); University Town of Shenzhen (2009–2012); Westlake University (2024); Jilin Jianzhu University (2024); Kunming Children's Hospital (2022); Novartis (China) (2013); Chongqing Academy of Environmental Science (2022); Peking University Cancer Hospital (2024); Sun Yat-sen Memorial Hospital (2024); Protein Express (United States) (2021); Zhongda Hospital Southeast University (2015–2017); Affiliated Hospital of Guizhou Medical University (2023); Peking University Shenzhen Hospital (2014); Winthrop Rockefeller Foundation (2026); Jilin Medical University (2024); Istituto Nazionale di Ricerca Metrologica (2012); Technical Institute of Physics and Chemistry (2025); Hangzhou Xixi hospital (2017); Jiangsu Province Hospital (2025); Guangzhou Medical University Cancer Hospital (2015); Guizhou Provincial People's Hospital (2023); Tumor Hospital of Guangxi Medical University (2016); University of Houston (2021–2026); Hunan Agricultural University (2023); Communication University of China (2008); Nanjing Medical University (2018–2025); Guangzhou Medical University (2015–2021); University of California, Berkeley (2017–2025)
Faculty Researcher
Upstream record may be merged OpenAlex, the source of these figures, lists 64 institutions in 5 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Lu Dai's research focuses on understanding disease mechanisms, particularly those involving viral infections and oncogenesis. Dai holds three principal investigator grants from the NIH totaling over $687,500. One grant supports the development of O’PROTACs-based degraders targeting an oncogenic viral protein, with funding of $229,500 from the National Institute of Allergy and Infectious Diseases. Another $152,000 grant from the National Institute of Dental and Craniofacial Research targets ILlRAP in virus-associated malignancies. A third grant of $306,000 from the National Institute of Dental and Craniofacial Research investigates the role of Macrophage Migration Inhibitory Factor (MIF) in KSHV-associated Malignancies.
Dai's publication record includes work on topics such as the reactivation of oncogenic viruses by SARS-CoV-2 and anti-COVID-19 drugs, and the potential threat of herpesvirus reactivation in the postpandemic era. Other publications explore the role of macrophage-derived exosomal miR-31-5p in promoting oral squamous cell carcinoma tumorgenesis and the kinetics of Fc galactosylation in enhancing immunoglobulin G hexamerization. Dai also has publications related to materials science, including work on vanadium-doped cobalt metaphosphate for efficient water and urea splitting and the development of pomegranate peel extract and nano ZnO co-reinforced polylactic acid film for active food packaging. Additionally, Dai has published on the association between cardiometabolic index and depression using NHANES data and developed LC–MS workflows for identifying residual HCPs in biotherapeutic products.
With an h-index of 23 and 197 total publications, Dai is recognized as a highly cited researcher. Key collaborators at the University of Arkansas for Medical Sciences include Steven R. Post, Shengyu Mu, Lindsey Barrett, and Samantha Kendrick, with whom Dai has co-authored multiple publications.
Metrics
- h-index: 24
- Publications: 199
- Citations: 1,702
Selected Publications
-
Targeting BRD2 and BRD4 inhibit the growth of KSHV-infected immortalized endothelial cells through suppression of LANA translation (2026)
-
Recent Advances in Development of Kaposi's Sarcoma‐Associated Herpesvirus‐Latency‐Associated Nuclear Antigen Targeted Therapies (2025)
-
Developing new ceramide analogs against non-small cell lung cancer (NSCLC) (2024)
-
Human endogenous retrovirus type K encoded Np9 oncoprotein induces DNA damage response (2024)
-
Development of human endogenous retrovirus type K‐ related treatments for human diseases (2024)
-
Role of lymphatic endothelium specific hyaluronan receptor 1 in virus infection and associated diseases (2024)
-
Coinfections with additional oncoviruses in HPV+ individuals: Status, function and potential clinical implications (2024)
Federal Grants 3 $687,500 total
Role of Macrophage Migration Inhibitory Factor (MIF) in KSHV-associated Malignancies
Development of O’PROTACs-based degraders targeting an oncogenic viral protein
Collaboration Network
Top Collaborators
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- SARS‐CoV‐2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?
- The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways
- Kaposi's sarcoma‐associated herpesvirus and extracellular vesicles
- Role of EIF4G1 network in non‐small cell lung cancers (NSCLC) cell survival and disease progression
Showing 5 of 15 shared publications
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- SARS‐CoV‐2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?
- The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways
- Role of EIF4G1 network in non‐small cell lung cancers (NSCLC) cell survival and disease progression
- Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target
Showing 5 of 10 shared publications
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- SARS‐CoV‐2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?
- The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways
- Role of EIF4G1 network in non‐small cell lung cancers (NSCLC) cell survival and disease progression
- Echinomycin as a promising therapeutic agent against KSHV-related malignancies
Showing 5 of 7 shared publications
- Role of EIF4G1 network in non‐small cell lung cancers (NSCLC) cell survival and disease progression
- Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target
- Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas
- Echinomycin as a promising therapeutic agent against KSHV-related malignancies
- Human endogenous retrovirus type K encoded Np9 oncoprotein induces DNA damage response
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- Echinomycin as a promising therapeutic agent against KSHV-related malignancies
- Activation of IL1 signaling molecules by Kaposi’s sarcoma-associated herpesvirus
- Oral Shedding of an Oncogenic Virus Alters the Oral Microbiome in HIV+ Patients
- Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target
- Echinomycin as a promising therapeutic agent against KSHV-related malignancies
- Oral Shedding of an Oncogenic Virus Alters the Oral Microbiome in HIV+ Patients
- Targeting BRD2 and BRD4 inhibit the growth of KSHV-infected immortalized endothelial cells through suppression of LANA translation
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- Kaposi's sarcoma‐associated herpesvirus and extracellular vesicles
- Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- Echinomycin as a promising therapeutic agent against KSHV-related malignancies
- Activation of IL1 signaling molecules by Kaposi’s sarcoma-associated herpesvirus
- The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways
- Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target
- Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas
- SARS‐CoV‐2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?
- Echinomycin as a promising therapeutic agent against KSHV-related malignancies
- Activation of IL1 signaling molecules by Kaposi’s sarcoma-associated herpesvirus
- Human endogenous retrovirus type K encoded Np9 oncoprotein induces DNA damage response
- Development of human endogenous retrovirus type K‐ related treatments for human diseases
- Targeting BRD2 and BRD4 inhibit the growth of KSHV-infected immortalized endothelial cells through suppression of LANA translation
- Kaposi's sarcoma‐associated herpesvirus and extracellular vesicles
- Role of EIF4G1 network in non‐small cell lung cancers (NSCLC) cell survival and disease progression
- Role of EIF4G1 network in non‐small cell lung cancers (NSCLC) cell survival and disease progression
- Oral Shedding of an Oncogenic Virus Alters the Oral Microbiome in HIV+ Patients
Similar Researchers
Based on overlapping research topics